Form 4: Immunome CFO Receives Stock Grant
Insider Transaction (Form 4)
Max Rosett, Chief Financial Officer of Immunome Inc., reported multiple transactions in common stock on July 23, 2026.
Summary
- Grant/award: acquired 47,250 Common Stock on July 23, 2026; holds 101,287 after (Direct).
- Grant/award: acquired 94,500 Employee Stock Option (right to buy) on July 23, 2026; holds 94,500 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Max Rosett — Officer (Chief Financial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-23 | Grant/award | Common Stock | 47,250 | — | — | 101,287 |
| 2026-07-23 | Grant/award | Employee Stock Option (right to buy) | 94,500 | — | — | 94,500 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-23 | Grant/award (47,250 shares) |
| 2026-07-23 | Grant/award (94,500 shares) |
Keywords
insider transaction, Form 4, IMNM, Immunome Inc., neutral, Max Rosett
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.